Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.
Its lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine.

Company Growth (employees)
Type
Public
HQ
Bothell, US
Founded
2004
Size (employees)
176 (est)
Alder BioPharmaceuticals was founded in 2004 and is headquartered in Bothell, US

Key People at Alder BioPharmaceuticals

Randall Schatzman

Randall Schatzman

President & CEO
John Latham

John Latham

Chief Scientific Officer
Larry Benedict

Larry Benedict

Vice President, Finance
Mark Litton

Mark Litton

Chief Business Officer and Treasurer

Alder BioPharmaceuticals Office Locations

Alder BioPharmaceuticals has an office in Bothell
Bothell, US (HQ)
11804 North Creek Parkway

Alder BioPharmaceuticals Data and Metrics

Alder BioPharmaceuticals Financial Metrics

USD

Net income (Q1, 2017)

(100.3 m)

EBIT (Q1, 2017)

(100.7 m)

Market capitalization (22-Aug-2017)

461.4 m

Cash (31-Mar-2017)

79.7 m
Alder BioPharmaceuticals's current market capitalization is $461.4 m.
USDFY, 2014FY, 2015FY, 2016

Cost of goods sold

113 k

R&D expense

33.4 m69.6 m132.8 m

General and administrative expense

12.5 m16.7 m26.1 m

Operating expense total

45.9 m86.3 m158.9 m

EBIT

8.8 m(86.3 m)(157.9 m)

Interest expense

88 k

Interest income

44 k702 k2 m

Net Income

8.9 m(85.5 m)(156.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cost of goods sold

113 k113 k

R&D expense

9.4 m7 m11 m14.1 m22.9 m27.6 m33.8 m29.5 m90.7 m

General and administrative expense

2.7 m3.2 m3.7 m3.9 m4.3 m6 m6.5 m6.2 m10 m

Operating expense total

12.1 m10.2 m14.7 m18 m27.2 m33.7 m40.3 m35.7 m100.7 m

EBIT

(7.4 m)28.6 m(14.7 m)(18 m)(27.2 m)(33.7 m)(39.2 m)(35.7 m)(100.7 m)

Interest income

9 k18 k59 k74 k248 k415 k529 k549 k485 k

Net Income

(7.4 m)28.6 m(14.7 m)(17.7 m)(27 m)(33.4 m)(38.9 m)(35.1 m)(100.3 m)
USDFY, 2014FY, 2015FY, 2016

Cash

46.8 m206.5 m116.2 m

Accounts Receivable

113 k113 k

Inventories

28.2 m936 k

Current Assets

60.7 m322.2 m393.2 m

PP&E

1.2 m2 m7.1 m

Total Assets

64.4 m400 m409.2 m

Accounts Payable

1.9 m4.7 m10.4 m

Current Liabilities

5 m12.4 m25.9 m

Total Liabilities

26.4 m

Additional Paid-in Capital

196.1 m610.4 m761.5 m

Retained Earnings

(136.9 m)(222.4 m)(378.6 m)

Total Equity

387.5 m382.8 m

Financial Leverage

1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

70.3 m57.6 m209.9 m408 m234 m178 m230 m170.6 m79.7 m

Accounts Receivable

57 k81 k113 k113 k113 k

Inventories

936 k936 k936 k

Current Assets

81.8 m73.8 m241.6 m442.1 m319.8 m319.7 m464.1 m428 m310.3 m

PP&E

1.2 m1.1 m1.3 m1.4 m1.3 m2.5 m5.2 m6.6 m6.8 m

Total Assets

85.6 m75.8 m242.9 m443.5 m426.3 m372.4 m474.4 m443.6 m317.8 m

Accounts Payable

2.8 m1.8 m2.2 m2.4 m7.7 m9.6 m8.4 m5.7 m20.3 m

Current Liabilities

23.2 m10.7 m6.6 m6.7 m14.5 m14.6 m16.2 m16.8 m29.6 m

Additional Paid-in Capital

194.5 m194.9 m387.8 m605.9 m607.8 m613.5 m752.6 m756.4 m766.7 m

Retained Earnings

(158.6 m)(130 m)(151.6 m)(169.2 m)(196.2 m)(255.7 m)(294.6 m)(329.7 m)(479 m)

Total Equity

436.7 m411.7 m357.7 m458.1 m426.7 m287.8 m

Financial Leverage

1 x1 x1 x1 x1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

8.9 m(85.5 m)(156.3 m)

Depreciation and Amortization

701 k751 k1.7 m

Accounts Receivable

203 k113 k113 k

Inventories

95 k(936 k)

Accounts Payable

(312 k)2.8 m5.5 m

Cash From Operating Activities

(47.7 m)(81.2 m)(159.7 m)

Purchases of PP&E

(649 k)(1.2 m)(6.6 m)

Cash From Investing Activities

(9.7 m)(167.3 m)(67.7 m)

Cash From Financing Activities

81 m408.2 m137.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.4 m)28.6 m(14.7 m)(17.7 m)(27 m)(33.4 m)(38.9 m)(35.1 m)(100.3 m)

Accounts Receivable

57 k81 k113 k113 k113 k

Inventories

936 k936 k936 k

Accounts Payable

2.8 m1.8 m2.2 m2.4 m7.7 m9.6 m8.4 m5.7 m20.3 m
Y, 2017

Financial Leverage

1.1 x

Alder BioPharmaceuticals Market Value History

Traffic Overview of Alder BioPharmaceuticals

Alder BioPharmaceuticals Online and Social Media Presence

Alder BioPharmaceuticals Company Life and Culture

You may also be interested in